Results 21 to 30 of about 4,310 (188)

Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication)

Japanese Dental Science Review, 2019
Summary: Generally, CT and MR images of antiresorptive agent-related osteonecrosis of the jaw (ARONJ)/medication-related osteonecrosis of the jaw (MRONJ) show nonspecific findings as seen in active osteomyelitis．However, there are some characteristics as
Akira Baba, Hiroya Ojiri, Tazuko K. Goto, Koshi Ikeda, Hideomi Yamauchi, Nobuhiro Ogino, Takuji Mogami   +6 more
doaj   +1 more source

Osteonecrosis of The Jaw; Medication- Related Osteonecrosis of the jaw (MRONJ)

SONDE (Sound of Dentistry), 2021
Sejak tahun 2004, dilaporkan terjadinya osteonecrosis of the jaw pada pasien osteoporosis yang mengkonsumsi bifosfonat, walaupun hal tersebut lebih sedikir dibandingkan kejadian osteonecrosis of the jaw pada penderita kanker yang mendapat terapi bifosfonat secara intravena.
openaire   +2 more sources

Medication-related osteonecrosis of the jaw: An update

National Journal of Maxillofacial Surgery, 2022
Antiresorptive medications, such as bisphosphonates and denosumab, are an important class of medication used to treat a wide range of diseases from osteoporosis to multiple myeloma. Unfortunately, they are also associated with a rare but devastating side effect - medication-related osteonecrosis of the jaw (MRONJ). First reported in 2003, much research
openaire   +2 more sources

Plasma Therapy for Medication-Related Osteonecrosis of the Jaws- A Case Report

Case Reports in Clinical Practice, 2023
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of anti-bone resorption medications. Nowadays antiresorptive medications like bisphosphonate and monoclonal antibodies like denosumab that have been prescribed for bone disorders and ...
Maryam Jalili Sadrabad, Elham Saberian
doaj   +1 more source

RANK-Ligand inhibitor associated osteonecrosis of the jaw

GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2013
Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis.
Rashad, Ashkan, Smeets, Ralf, Heiland, Max   +2 more
doaj   +1 more source

An unusual case of bone regeneration of a necrotic mandible with pathologic fracture in an elderly hemodialysis patient with medication-related osteonecrosis of the jaw: a case report and review of the literature

Journal of Medical Case Reports, 2021
Background Bisphosphonates are frequently used for osteoporosis. Medication-related osteonecrosis of the jaw, a complication of bone-modifying agents, including bisphosphonates or angiogenic inhibitors, can be challenging to treat in elderly patients ...
Kunio Yoshizawa, Akinori Moroi, Ran Iguchi, Akihiro Takayama, Junko Goto, Yutaka Takayama, Koichiro Ueki   +6 more
doaj   +1 more source

Intraosseous Squamous Cell Carcinoma Associated with Denosumab-Induced Osteonecrosis of the Jaw

Applied Sciences, 2021
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with the use of different drugs administered in the treatment of malignant neoplasms or metastases and in antiresorptive therapies. Since 2010, denosumab, a monoclonal antibody whose
Sandra Bacián Martínez, Carlos Navarro Cuéllar, Carlos Navarro Vila, Edurne Palacios Weiss, Roser Pujol Romanyá, Álvaro del Amo Fernández de Velasco, Margarita Escrig de Teijeiro, José Luis del Castillo Pardo de Vera, Irene Rodríguez Pérez, Arturo Sánchez-Pérez, José J. Zamorano-León, Antonio López-Farré, María Isabel García-Hidalgo Alonso, Ignacio Navarro Cuéllar   +13 more
doaj   +1 more source

Medication-related Osteonecrosis of the Jaw [PDF]

Radiology, 2021
null Sajeev R. Ezhapilli Chennan, MBBS, null Maria Andrea Parra Corral, MD, null Ronald T. Smith Jr, MD, null Claudia Jordan-Guedes   +3 more
openaire   +3 more sources

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

Dentistry Journal, 2018
The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients.
Vittorio Fusco, Giuseppina Campisi, Paul de Boissieu, Federico Monaco, Anna Baraldi, Gianmauro Numico, Alberto Bedogni   +6 more
doaj   +1 more source

A clinical retrospective study of implant as a risk factor for medication-related osteonecrosis of the jaw: surgery vs loading?

Maxillofacial Plastic and Reconstructive Surgery, 2023
Background Risk factors for developing medication-related osteonecrosis of the jaw (MRONJ) include the general condition of the patient, smoking habit, poor oral hygiene, and the type, duration, and administration route of the drug, dentoalveolar surgery,
Yong-Dae Kwon, Hyunmi Jo, Jae-Eun Kim, Joo-Young Ohe   +3 more
doaj   +1 more source